Structural Basis for Rational Design of Inhibitors Targeting Trypanosoma cruzi Sterol 14α-Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition
暂无分享,去创建一个
M. Waterman | Z. Wawrzak | F. Villalta | R. Di Santo | G. Lepesheva | D. De Vita | Laura Friggeri | S. Tortorella | Laura Friggeri | Tatiana Y. Hargrove | Girish Rachakonda | Amanda D. Williams | Zdzislaw Wawrzak | Roberto Di Santo | Daniela De Vita | Michael R. Waterman | Silvano Tortorella | Fernando Villalta | Galina I. Lepesheva | G. Rachakonda
[1] M. Waterman,et al. Crystal Structures of Trypanosoma brucei Sterol 14α-Demethylase and Implications for Selective Treatment of Human Infections*♦ , 2009, The Journal of Biological Chemistry.
[2] M. Gelb,et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[3] R. Durvasula,et al. Globalization of Chagas Disease: A Growing Concern in Nonendemic Countries , 2012 .
[4] R. Isturiz,et al. Chagas Disease , 2021, Neglected Tropical Diseases.
[5] M. Gelb,et al. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. , 2005, Journal of medicinal chemistry.
[6] T. Omura,et al. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.
[7] S. Montgomery,et al. Trypanosoma cruzi and Chagas' Disease in the United States , 2011, Clinical Microbiology Reviews.
[8] M. J. Uddin,et al. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. , 2009, Journal of medicinal chemistry.
[9] J. Urbina,et al. Ergosterol biosynthesis and drug development for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.
[10] David M. Shackleford,et al. Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib , 2012, Antimicrobial Agents and Chemotherapy.
[11] M. Waterman,et al. Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). , 2011, Advances in parasitology.
[12] Mitch Leslie,et al. Infectious diseases. Drug developers finally take aim at a neglected disease. , 2011, Science.
[13] M. Waterman,et al. Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. , 2007, Biochimica et biophysica acta.
[14] M. Waterman,et al. CYP51 from Trypanosoma cruzi , 2006, Journal of Biological Chemistry.
[15] G. Lepesheva. Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? , 2013, Expert opinion on drug discovery.
[16] J. Clayton. Chagas disease: pushing through the pipeline , 2010, Nature.
[17] P. Hotez,et al. Neglected Infections of Poverty in Texas and the Rest of the United States: Management and Treatment Options , 2012, Clinical pharmacology and therapeutics.
[18] M. Waterman,et al. Sterol 14α-Demethylase Cytochrome P450 (CYP51), a P450 in all Biological Kingdoms , 2007 .
[19] M. Waterman,et al. Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruzi* , 2010, The Journal of Biological Chemistry.
[20] M. Chorilli,et al. Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity. , 2014, Journal of medicinal chemistry.
[21] L. Filardi,et al. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[22] M. Waterman,et al. In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruzi , 2013, Antimicrobial Agents and Chemotherapy.
[23] M. Waterman,et al. VNI cures acute and chronic experimental Chagas disease. , 2013, The Journal of infectious diseases.
[24] S. Pratap,et al. Cellular Response to Trypanosoma cruzi Infection Induces Secretion of Defensin α-1, Which Damages the Flagellum, Neutralizes Trypanosome Motility, and Inhibits Infection , 2013, Infection and Immunity.
[25] Paul W. Alexander,et al. Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease , 2013, The Journal of Biological Chemistry.
[26] M. Waterman,et al. Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. , 2007, Chemistry & biology.
[27] C. Bern. Antitrypanosomal therapy for chronic Chagas' disease. , 2011, The New England journal of medicine.
[28] M. Lima,et al. Trypanosoma cruzi trypomastigote clones differentially express a parasite cell adhesion molecule. , 1989, Molecular and biochemical parasitology.
[29] M. Waterman,et al. Structural basis for conservation in the CYP51 family. , 2011, Biochimica et biophysica acta.
[30] Peter J. Hotez,et al. Neglected Infections of Poverty in the United States of America , 2008, PLoS neglected tropical diseases.
[31] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[32] F. D. D'Auria,et al. Synthesis and antifungal activity of a new series of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives. , 2012, European journal of medicinal chemistry.
[33] C. Zamperini,et al. New Promising Compounds with in Vitro Nanomolar Activity against Trypanosoma cruzi. , 2013, ACS medicinal chemistry letters.
[34] M. Waterman,et al. CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds. , 2012, International journal for parasitology. Drugs and drug resistance.